Cellular Distribution and Clinical Value of Urokinase-Type Plasminogen Activator, Its Receptor, and Plasminogen Activator Inhibitor-2 in Esophageal Squamous Cell Carcinoma
- 29 February 2000
- journal article
- Published by Elsevier in The American Journal of Pathology
- Vol. 156 (2) , 567-575
- https://doi.org/10.1016/s0002-9440(10)64761-x
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 42 references indexed in Scilit:
- Mitogenic Effects of Urokinase on Melanoma Cells Are Independent of High Affinity Binding to the Urokinase ReceptorPublished by Elsevier ,1998
- Plasminogen activators in oesophageal carcinomaBritish Journal of Surgery, 1996
- Plasminogen Activator Inhibitor Type 2 Inhibits Tumor Necrosis Factor α-induced ApoptosisJournal of Biological Chemistry, 1995
- A Novel Matrix Attachment Region DNA Binding Motif Identified Using a Random Phage Peptide LibraryPublished by Elsevier ,1995
- Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancerInternational Journal of Cancer, 1995
- Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon CancerJapanese Journal of Cancer Research, 1995
- Urokinase receptor and colorectal cancer survivalThe Lancet, 1994
- Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancerThe Lancet, 1994
- Differential protease expression by cutaneous squamous and basal cell carcinomas.Journal of Clinical Investigation, 1991
- Non-radioactive detection of nerve growth factor receptor (NGFR) mRNA in rat brain using in situ hybridization histochemistry.Journal of Histochemistry & Cytochemistry, 1991